Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study

Fig. 3

WOMAC Pain responders. The proportion of patients achieving ≥30% (A), ≥50% (B), ≥70% (C), or ≥90% (D) reductions from baseline in WOMAC Pain at weeks 2, 4, 8, 16, and 56 is shown. Proportions shown above each bar are rounded to the nearest percent. *Unadjusted p ≤ 0.05 versus NSAID. NSAID, nonsteroidal anti-inflammatory drug; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us